DP Technology Nominates CNS Penetrable Lp-PLA2 Inhibitor as Development Candidate for Alzheimer's Disease
DP Technology, an "AI for Science" paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer's disease (AD).